Report Id: SNS/HC/1288 | May 2022 | Region: Global | 125 Pages
Report Scope & Overview:
The Hypoparathyroidism Treatment Market Size was valued at USD 1.28 billion in 2021 and is expected to reach USD 2.25 billion by 2028, and grow at a CAGR of 8.4% over the forecast period 2022-2028.
Hypoparathyroidism is an uncommon disorder in which the activity of the parathyroid glands is reduced. The most prevalent cause of hypoparathyroidism in patients is when their parathyroid glands are removed or damaged during surgery. It is characterised by low parathyroid hormone secretion and can result in a significant decline in blood calcium levels as well as elevated phosphorus levels. Hypoparathyroidism symptoms range from modest tingling in the fingers, hands, or lips to severe and painful muscle cramps. Patients may experience convulsions and severe muscle cramps across their entire body. PTH shortage due to poor secretion and PTH inability to elicit a response from the bones and kidneys are the two types of hypoparathyroidism.
Supplementing the body with vitamins and minerals to restore calcium and phosphorus levels in the blood is one of the most popular hypoparathyroidism treatments. This can involve things like taking calcium carbonate tablets or getting a lot of vitamin D. The latter entails the ingestion of calcitriol and works by improving the body's calcium absorption rate. Other therapy option is to inject PTH every day using an FDA-approved injection.
Hypoparathyroidism is a condition in which the parathyroid glands do not produce enough hormone. Hypoparathyroidism can be caused by a wide variety of factors, including parathyroid gland injury or removal, DiGeorge syndrome, a genetic illness, autoimmune disease, cancer radiation treatment, and a low magnesium level. The purpose of parathyroid hormone is to keep the blood phosphorus and calcium levels in check. Hypoparathyroidism symptoms arise when the blood calcium level is low and the phosphorus level is high, causing the human body to exhibit symptoms such as muscle spasms, hair loss, dry skin, numbness, and convulsions. Both children and adults can develop hypoparathyroidism. If a child has hypoparathyroidism, symptoms include poor tooth development, vomiting, headaches, and mental issues.
Side effects Increased Thoracic Surgery and Cancer Incidence
Investing more in R&D
Government Support for New Drug Development
The increasing increase in demand for hypothyroidism biologics
The rise of biologics is expected to bring lucrative
Long Clinical Approval Processes
IMPACT OF COVID-19
The COVID-19 has had a significant effect on the health industry. While research trials for uncommon diseases have been delayed or postponed until 2020 due to the high emphasis placed on the development of life-saving medications, the market for hypoparathyroidism is projected to experience a short-term fall through 2021.
Government financing and subsidies to assist the development of new hormonal therapies, as well as the relaxing of regulatory laws, are projected to give significant chances for industry expansion. As a result, during the projected period, the market is expected to increase at a stable rate.
Low parathyroid hormone secretions cause hypocalcemia. To normalize the insufficiency, doctors use calcium supplements as the first line of treatment.
By Route of Administration:
Due to increased product introductions and a strong pipeline, the oral sector had the highest market share by route of administration. Various elements, such as drug delivery speed, efficacy, and bioavailability, are expected to drive the oral segment's development. The oral mode of administration is effective for medications with a medium to high oral availability.
Oral therapies reduce the need for central lines for intravenous drug administration, lowering the risk of problems and hospitalization. One of the primary elements projected to promote segment growth is the advancement of promising new drugs and possible clinical pipeline candidates.
Due to the general growing number of facilities and patient accessibility, hospital and retail sales are predicted to have the largest market share among all distribution channels. Additionally, one of the primary reasons driving market expansion throughout the projection period is the rapid delivery of medicines.
Some of the major key players are as follows: Amgen Inc., Ascendis Pharma A/S, BionPharma Inc., Entera Bio Ltd., Extend Biosciences, Inc., F. Hoffmann-La Roche Ltd, ProLynx, Inc., Takeda Pharmaceutical Company Limited.
KEY MARKET SEGMENTS:
By Product Type
Vitamin D Analogue
By Route of Administration
By Distribution Channel
With a market share of 39.5 percent in 2021, North America dominated the Hypoparathyroidism Treatment Market. This can be linked to the rise in thyroid-related disorders and pharmaceutical companies' efforts to develop novel formulations. The market in this region is growing due to an increase in the number of thoracic procedures and the incidence of cancer.
However, due to increased government initiatives to promote awareness and the presence of generic manufacturers, Asia Pacific is expected to develop at a faster CAGR over the projection period 2022-2028. The market in this region is growing due to new technological breakthroughs in the treatment of hypoparathyroidism.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 1.28 Billion|
|Market Size by 2028||US$ 2.25 Billion|
|CAGR||CAGR of 8.4% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Product Type (Parathyroid Hormone (Natpara), Vitamin D Analogue (Vitamin D2, Vitamin D3), Calcium Supplements)
• By Route of Administration (Parenteral, Oral)
• By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Amgen Inc., Ascendis Pharma A/S, BionPharma Inc., Entera Bio Ltd., Extend Biosciences, Inc., F. Hoffmann-La Roche Ltd, ProLynx, Inc., Takeda Pharmaceutical Company Limited.|
|DRIVERS||• Side effects Increased Thoracic Surgery and Cancer Incidence
• Investing more in R&D
• Government Support for New Drug Development
|RESTRAINTS||• Side effects
• High cost
Frequently Asked Questions (FAQ) :
Hypoparathyroidism Treatment market is expected to grow at a CAGR of 8.4% over the forecast period 2022-2028.
Neurorehabilitation devices are Side effects, and High cost is the restraint of the Neurorehabilitation market.
Neurorehabilitation Market is divided into four segments and they are By Type, By Application Type, and, By End User Type
North America dominated the Hypoparathyroidism Treatment Market.
Due to increased product introductions and a strong pipeline, the oral sector had the highest market share by route of administration
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of Ukraine ware
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Hypoparathyroidism Treatment Market Segmentation, By Product Type
8.1 Parathyroid Hormone
8.2 Vitamin D Analogue
8.2.1 Vitamin D2
8.2.2 Vitamin D3
8.3 Calcium Supplements
9. Hypoparathyroidism Treatment Market Segmentation, By Route of Administration
10. Hypoparathyroidism Treatment Market Segmentation, By Distribution Channel
10.1 Retail Pharmacies
10.2 Hospital Pharmacies
11. Regional Analysis
11.2 North America
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4.2 South Korea
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.3 South Africa
11.6 Latin America
11.6.3 Rest of Latin America
12. Company Profiles
12.1 Amgen Inc.
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.2 Ascendis Pharma A/S
12.3 BionPharma Inc.
12.4 Entera Bio Ltd.
12.5 Extend Biosciences, Inc.
12.6 F. Hoffmann-La Roche Ltd
12.7 ProLynx, Inc.
12.8 Takeda Pharmaceutical Company Limited.
13. Competitive Landscape
13.1 Competitive Benchmark
13.2 Market Share analysis
13.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.